Home › Trials › NCT06832007
Clinical trial Recruiting at 1 site Interventional Ages 18 to 60

Daily bright-light glasses to improve sleep and recovery in people with opioid use disorder

Official title: The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)

Run by University of Alabama at Birmingham · NCT06832007 · Data updated 2026-11-12

This trial will test whether wearing AYO bright-light glasses each morning can improve sleep patterns and support recovery in adults receiving medication for opioid use disorder.

More Opioid Use Disorder trials

Quick facts

Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment105 (estimated)
SponsorUniversity of Alabama at Birmingham
Academic / other
Locations1 site (Birmingham, Alabama)
StatusRecruiting
StartedSeptember 6, 2025
Main results expectedSeptember 16, 2028
Study endsSeptember 16, 2028
Registry record updatedOctober 9, 2026
Trial IDNCT06832007 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–60 with DSM-5 opioid use disorder who have used opioids for at least 12 months, are stabilized on methadone or buprenorphine (positive urine for these medications) with a stable dose for at least one month, fluent in English, and able to consent.

Probably not a fit

People not on opioid agonist therapy, those with unstable dosing or medical exclusions such as a history of prolonged loss of consciousness, seizures, pregnancy, or ferromagnetic implants that preclude MRI, and those outside the age range are unlikely to be eligible or to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with opioid use disorder who are stabilized on methadone or buprenorphine will be assigned to use AYO light glasses or a comparator AYO device and followed over a treatment period. The study collects both objective and subjective sleep measures and monitors circadian regularity and mood. Brain imaging (fMRI) is included as part of the research assessments to explore neural correlates. Outcomes will be compared between the AYO intervention and comparator groups to see if morning bright-light exposure improves sleep and related recovery measures.

Why it matters

Potential benefit: If successful, the intervention could improve sleep regularity and mood and potentially lower relapse risk for people on opioid agonist therapy.

How similar studies have gone: Bright light therapy has improved circadian and sleep outcomes in several psychiatric and neurological conditions and a pilot study showed better sleep in people with alcohol use disorder, but its effectiveness specifically in opioid use disorder remains limited and relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* All Participants
* Between 18 and 60 years old
* Fluent in English
* Able to provide written informed consent

OUD

* DSM-5 diagnosis of an OUD.
* ≥12 months of lifetime opioid use
* Positive on urine drug screen for buprenorphine or methadone
* Receiving opioid agonist therapy for OUD (e.g., methadone or buprenorphine) with a stable dose for the past month. Must have been stabilized on OMT medication, since the increasing of doses during induction phase might interfere with outcomes and unstable patients might experience strong withdrawal symptoms in the morning which makes them unsuitable for a home-based BLT.
* Other substance use was not exclusionary, but opioids were identified as primary.

Exclusion Criteria:

All Participants

* Head trauma with loss of consciousness for more than 30 minutes as determined by medical history.
* history of seizures/epilepsy.
* Pregnant and/or currently breast-feeding.
* Presence of ferromagnetic objects in the body that are contraindicated for MRI or fear of enclosed spaces.
* Eye disease including disease of the anterior and posterior segment of the eye, cataracts, retinopathy, glaucoma, amblyopia, scotoma, color or night blindness, corneal pathologies, macular degeneration, or retinitis pigmentosa reported by history or identified by eye exam
* History of eye surgery
* Chronic migraine triggered by bright light
* worked night shift or traveled across\>2 time zones in the past month

OUD

* diagnosis of substance use disorder other than for opioids that was deemed to be primary
* lifetime diagnosis of schizophrenia, bipolar disorder, or suicidality.
* History of light treatment
* Unstable dose of psychiatric medication (hypnotics, sleep aids, and antidepressants must be stable for 30 days before and during the study)

HC

* Current or past DSM-IV or DSM-5 diagnosis of a psychiatric disorder including substance use disorder (except for nicotine/caffeine).
* Current DSM-5 sleep-wake disorders including insomnia disorder

Where it's running

  • University of Alabama at Birmingham
    Birmingham, Alabama, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Opioid Use Disorder 579Circadian Rhythms 4fMRI Research 6University of Alabama at Birmingham 1432
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.